A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
Bradley J MonkChristine ParkinsonMyong Cheol LimDavid M O'MalleyAna OakninMichelle K WilsonRobert L ColemanDomenica LorussoPaul BessetteSharad GhamandeAthina ChristopoulouDiane ProvencherEmily PrendergastFuat DemirkiranOlga MikheevaOladapo O YekuAnita Chudecka-GlazMichael SchenkerRamey D LittellTamar SafraHung-Hsueh ChouMark A MorganVít DrochýtekJoyce N BarlinToon Van GorpFrederick Rand UelandGabriel LindahlCharles AndersonDearbhaile C CollinsKathleen M MooreFrederic MarméShannon Neville WestinIain A McNeishDanny ShihKevin K LinSandra GobleStephanie HumeKeiichi FujiwaraRebecca S KristeleitPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Rucaparib monotherapy is effective as first-line maintenance, conferring significant benefit versus placebo in patients with advanced ovarian cancer with and without HRD.